Amabile G, Di Ruscio A, Muller F et al (2015) Dissecting the role of aberrant DNA methylation in human leukaemia. Nat Commun 6:7091. https://doi.org/10.1038/ncomms8091
Bock C, Kiskinis E, Verstappen G et al (2011) Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144:439-452. https://doi.org/10.1016/j.cell.2010.12.032
Brewer BG, Mitchell RA, Harandi A, Eaton JW (2009) Embryonic vaccines against cancer: an early history. Experimental and molecular pathology 86:192-197. https://doi.org/10.1016/j.yexmp.2008.12.002
Chao MP, Gentles AJ, Chatterjee S et al (2017) Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell stem cell 20:329-344 e327. https://doi.org/10.1016/j.stem.2016.11.018
Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17:3520-3526. https://doi.org/10.1158/1078-0432.CCR-10-3126
de Almeida PE, Meyer EH, Kooreman NG et al (2014) Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat Commun 5:3903. https://doi.org/10.1038/ncomms4903
Dong W, Du J, Shen H et al (2010) Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load. Cancer immunology, immunotherapy : CII 59:1697-1705. https://doi.org/10.1007/s00262-010-0899-9
Gomes-Silva D, Srinivasan M, Sharma S et al (2017) CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 130:285-296. https://doi.org/10.1182/blood-2017-01-761320
Goyvaerts C, Breckpot K (2018) Towards a personalized iPSC-based vaccine. Nature biomedical engineering 2:277-278. https://doi.org/10.1038/s41551-018-0237-7
Haferlach T, Kohlmann A, Wieczorek L et al (2010) Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 28:2529-2537. https://doi.org/10.1200/JCO.2009.23.4732
Kato M, Manabe A (2018) Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int 60:4-12. https://doi.org/10.1111/ped.13457
Katz T, Avivi I, Benyamini N, Rosenblatt J, Avigan D (2014) Dendritic cell cancer vaccines: from the bench to the bedside. Rambam Maimonides Med J 5:e0024. https://doi.org/10.5041/RMMJ.10158
Kooreman NG, Kim Y, de Almeida PE et al (2018) Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. Cell stem cell 22:501-513 e507. https://doi.org/10.1016/j.stem.2018.01.016
Kotini AG, Chang CJ, Boussaad I et al (2015) Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat Biotechnol 33:646-655. https://doi.org/10.1038/nbt.3178
Kumano K, Arai S, Hosoi M et al (2012) Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 119:6234-6242. https://doi.org/10.1182/blood-2011-07-367441
Lato MW, Przysucha A, Grosman S, Zawitkowska J, Lejman M (2021) The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci 22 https://doi.org/10.3390/ijms22094502
Lee AS, Tang C, Rao MS, Weissman IL, Wu JC (2013) Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nature medicine 19:998-1004. https://doi.org/10.1038/nm.3267
Lee DF, Su J, Kim HS et al (2015) Modeling familial cancer with induced pluripotent stem cells. Cell 161:240-254. https://doi.org/10.1016/j.cell.2015.02.045
Li T, Zhang Y, Li Y et al (2021) Modeling leukemia with pediatric acute leukemia patient-derived iPSCs. Stem cell research 54:102404. https://doi.org/10.1016/j.scr.2021.102404
Li Y, Zeng H, Xu RH, Liu B, Li Z (2009) Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells 27:3103-3111. https://doi.org/10.1002/stem.234
Lu S, Zhang Z, Du P et al (2020) A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer. Clin Cancer Res 26:465-476. https://doi.org/10.1158/1078-0432.CCR-19-1395
Mallon BS, Hamilton RS, Kozhich OA, Johnson KR, Fann YC, Rao MS, Robey PG (2014) Comparison of the molecular profiles of human embryonic and induced pluripotent stem cells of isogenic origin. Stem cell research 12:376-386. https://doi.org/10.1016/j.scr.2013.11.010
Mamonkin M, Rouce RH, Tashiro H, Brenner MK (2015) A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood 126:983-992. https://doi.org/10.1182/blood-2015-02-629527
Markov O, Oshchepkova A, Mironova N (2019) Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles-A Novel Strategy for Enhancement of the Anti-tumor Immune Response. Front Pharmacol 10:1152. https://doi.org/10.3389/fphar.2019.01152
Munoz-Lopez A, Romero-Moya D, Prieto C et al (2016) Development Refractoriness of MLL-Rearranged Human B Cell Acute Leukemias to Reprogramming into Pluripotency. Stem cell reports 7:602-618. https://doi.org/10.1016/j.stemcr.2016.08.013
Ouyang X, Liu Y, Zhou Y et al (2021) Antitumor effects of iPSC-based cancer vaccine in pancreatic cancer. Stem cell reports 16:1468-1477. https://doi.org/10.1016/j.stemcr.2021.04.004
Patrick K, Vora A (2015) Update on biology and treatment of T-cell acute lymphoblastic leukaemia. Curr Opin Pediatr 27:44-49. https://doi.org/10.1097/MOP.0000000000000171
Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-924. https://doi.org/10.1200/JCO.2010.32.2537
Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nature medicine 10:909-915. https://doi.org/10.1038/nm1100
Sanchez-Martinez D, Baroni ML, Gutierrez-Aguera F et al (2019) Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood 133:2291-2304. https://doi.org/10.1182/blood-2018-10-882944
Suva ML, Rheinbay E, Gillespie SM et al (2014) Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157:580-594. https://doi.org/10.1016/j.cell.2014.02.030
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872. https://doi.org/10.1016/j.cell.2007.11.019
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676. https://doi.org/10.1016/j.cell.2006.07.024
Xiang X, Wang J, Lu D, Xu X (2021) Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal transduction and targeted therapy 6:75. https://doi.org/10.1038/s41392-021-00484-9
Yaddanapudi K, Li C, Eaton JW (2018) Vaccination with induced pluripotent stem cells confers protection against cancer. Stem Cell Investig 5:23. https://doi.org/10.21037/sci.2018.07.03
Yaddanapudi K, Mitchell RA, Putty K et al (2012) Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible? PLoS One 7:e42289. https://doi.org/10.1371/journal.pone.0042289
Zhang Z, Lu S, Dunmall LSC et al (2020) Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime. Front Immunol 11:1996. https://doi.org/10.3389/fimmu.2020.01996